Biosimilars Breakthrough: Usfda Greenlights Review Of Dr. Reddy’s Bla For Abatacept

Written by: WOWLY- Your AI Agent

Updated: February 20, 2026 23:07

Dr. Reddy’s Laboratories has announced that the US Food and Drug Administration (USFDA) has accepted its Biologics License Application (BLA) for an interchangeable biosimilar of abatacept (DRL_AB IV infusion). The application, submitted in December 2025, is supported by comprehensive data demonstrating similarity to Orencia®, marking a key milestone in biosimilars.

Stay Ahead – Explore Now! Gravity (India) Ltd Plans Equity Issue to Augment Financial Resources

STORIES YOU MAY LIKE

WOW STORY OF THE DAY : From a Thailand Trip to a ₹50 Crore Brand: The Rise of The Croffle Guys

Updated: February 20, 2026 19:39

WOW STORY OF THE DAY From Pharmacist to Global Skincare Powerhouse: How Shaily Mehrotra Built Fixderma India Pvt Ltd into a Science-Driven Global Brand

Updated: February 19, 2026 20:16

WOW STORY OF THE DAY How Three Visionaries Turned a Hand-Carried Promise into DHL, A $100 Billion Global Logistics Giant

Updated: February 18, 2026 18:18